Antoine Regnault

4.2k total citations · 1 hit paper
79 papers, 2.1k citations indexed

About

Antoine Regnault is a scholar working on Hematology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Antoine Regnault has authored 79 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 11 papers in Genetics and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Antoine Regnault's work include Health Systems, Economic Evaluations, Quality of Life (8 papers), Multiple Myeloma Research and Treatments (7 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers). Antoine Regnault is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (8 papers), Multiple Myeloma Research and Treatments (7 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers). Antoine Regnault collaborates with scholars based in France, United States and United Kingdom. Antoine Regnault's co-authors include Véronique Sebille, L. Moret, Emmanuelle Anthoine, Jean-Benoît Hardouin, Skye Barbic, Tom Willgoss, Juliette Meunier, Muriel Viala-Danten, Thomas Morel and Stefan Cano and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Antoine Regnault

71 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures

2014 738 citations Antoine Regnault et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antoine Regnault France	20	311	280	273	221	194	79	2.1k
Alan L. Shields United States	23	355 1.1×	224 0.8×	172 0.6×	170 0.8×	166 0.9×	72	2.5k
Pedro Serrano‐Aguilar Spain	27	632 2.0×	154 0.6×	160 0.6×	322 1.5×	67 0.3×	97	2.3k
Havi Murad Israel	20	188 0.6×	165 0.6×	121 0.4×	279 1.3×	192 1.0×	50	1.7k
Kathleen Beusterien United States	31	256 0.8×	141 0.5×	140 0.5×	508 2.3×	219 1.1×	101	3.2k
Jean Saunders Ireland	25	196 0.6×	67 0.2×	238 0.9×	385 1.7×	116 0.6×	89	2.1k
Eric Gardiner United Kingdom	25	413 1.3×	127 0.5×	191 0.7×	295 1.3×	62 0.3×	54	2.5k
Joost G. Daams Netherlands	35	483 1.6×	161 0.6×	211 0.8×	209 0.9×	53 0.3×	116	3.5k
Emmanuel Écosse France	21	161 0.5×	401 1.4×	119 0.4×	130 0.6×	55 0.3×	45	2.1k
Wing S. Wong Hong Kong	30	397 1.3×	92 0.3×	222 0.8×	305 1.4×	80 0.4×	79	3.4k
Joey S.W. Kwong China	13	414 1.3×	157 0.6×	189 0.7×	118 0.5×	44 0.2×	24	2.5k

Countries citing papers authored by Antoine Regnault

Since Specialization

Citations

This map shows the geographic impact of Antoine Regnault's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antoine Regnault with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antoine Regnault more than expected).

Fields of papers citing papers by Antoine Regnault

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antoine Regnault. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antoine Regnault. The network helps show where Antoine Regnault may publish in the future.

Co-authorship network of co-authors of Antoine Regnault

This figure shows the co-authorship network connecting the top 25 collaborators of Antoine Regnault. A scholar is included among the top collaborators of Antoine Regnault based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antoine Regnault. Antoine Regnault is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Palmer, Jeanne, Antoine Regnault, Shiyuan Zhang, et al.. (2024). Association between hemoglobin (Hb) improvement and patient-reported outcomes (PROs) in patients (pts) with myelofibrosis (MF) and anemia: Post hoc pooled analysis of momelotinib (MMB) phase 3 trials.. Journal of Clinical Oncology. 42(16_suppl). 6574–6574. 2 indexed citations

Regnault, Antoine, et al.. (2024). PCR254 Evidence To Support the Use of the Functional Assessment of Cancer Therapy – General Item GP5 (FACT-GP5) To Assess Comparative Tolerability Endpoint: Results From the LIBRETTO-531 Trial. Value in Health. 27(6). S343–S344.

Markowitz, Jessica T., et al.. (2024). Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library. Journal of Patient-Reported Outcomes. 8(1). 8–8. 2 indexed citations

Norquist, Josephine M., et al.. (2024). MSR190 Psychometric Analysis of the Patient-Reported Plexiform Neurofibromas Quality of Life Measure Using KOMET Study Data. Value in Health. 27(12). S476–S476. 1 indexed citations

Regnault, Antoine, et al.. (2023). Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO. Neurology and Therapy. 12(5). 1573–1590. 12 indexed citations

Hess, Lisa M., et al.. (2023). CO115 Psychometric Evaluation of Customized Lymphoma-Specific Symptom Measures Using the EORTC QLQ-C30 and Item Library: Data from a Phase 1/2 Clinical Trial of Pirtobrutinib. Value in Health. 26(6). S36–S36.

Regnault, Antoine, et al.. (2023). Providing meaningful interpretation of performance outcome measures by co-calibration with patient-reported outcomes through the Rasch model: illustration with multiple sclerosis measures. Journal of Biopharmaceutical Statistics. 35(5). 851–871.

McGregor, Bradley A., Peter H. O’Donnell, Arjun Vasant Balar, et al.. (2022). Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. European Urology. 81(5). 515–522. 20 indexed citations

Regnault, Antoine, Farrah Pompilus, Rafael Bejar, et al.. (2021). Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30. Journal of Patient-Reported Outcomes. 5(1). 60–60. 8 indexed citations

10.

Gorsh, Boris, et al.. (2020). PCN309 Methodology for Evaluating Meaningful Change Thresholds in Patient-Reported Outcome (PRO) Measures for Corneal Events in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Single-Agent Belantamab Mafodotin (BELAMAF). Value in Health. 23. S477–S477. 2 indexed citations

11.

Arbuckle, Rob, et al.. (2020). Testing and Psychometric Validation of a Pediatric Instrument to Self-Assess Symptoms of the Common Cold. Patient. 14(1). 101–117. 3 indexed citations

12.

Regnault, Antoine, Babak Boroojerdi, Juliette Meunier, et al.. (2019). Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort. Journal of Neurology. 266(8). 1927–1936. 119 indexed citations

13.

Edgar, Chris J., et al.. (2016). Cross-Cultural Adaptation of the Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) and the Caregiver Global Impression Scales in 13 Languages. Value in Health. 19(7). A389–A389.

14.

Rofail, Diana, et al.. (2015). Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin. Quality of Life Research. 25(1). 201–211. 16 indexed citations

15.

Regnault, Antoine, et al.. (2014). Pooling of cross-cultural PRO data in multinational clinical trials: How much can poor measurement affect statistical power?. Quality of Life Research. 24(2). 273–277. 12 indexed citations

16.

Regnault, Antoine & Michael Herdman. (2014). Using quantitative methods within the Universalist model framework to explore the cross-cultural equivalence of patient-reported outcome instruments. Quality of Life Research. 24(1). 115–124. 32 indexed citations

17.

Arnould, Benoît, et al.. (2013). Validation of Accept, a New Generic Measure to Assess How Patients with Chronic Diseases Balance Between the Advantages and Disadvantages of Following the Recommended Treatment Regimen in Real-life. Value in Health. 16(7). A335–A335. 6 indexed citations

18.

Seventer, Robert van, C. J. de Vos, Maurice J.M.M. Giezeman, et al.. (2012). Validation of the Dutch Version of the DN4 Diagnostic Questionnaire for Neuropathic Pain. Pain Practice. 13(5). 390–398. 51 indexed citations

19.

Regnault, Antoine, Maria‐Magdalena Balp, Károly Kulich, & Muriel Viala-Danten. (2012). Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis. Journal of Cystic Fibrosis. 11(6). 494–501. 44 indexed citations

20.

Gilet, Hélène, et al.. (2011). PCN199 An Evaluation of Statistical Methods Used to Analyse Patient-Reported Outcomes (PRO) Data in Published Metastatic Cancer Studies. Value in Health. 14(7). A471–A471.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact